Member Info for Professor1

Zag

That is big accusation you are making. The December RNS could not have been any more clearer.

GLA

@Howdy

Explain " incompetence of owner"

Huge amount of planning would have been undertaken in this, its only a matter of time. Big news ahead

GLA

Topped up first thing 38848

GLA

Excellent.

GLA

Super news. A step forwards towards big prize(s).

GLA

@roger

We might get ground breaking news this week!!

GLA

@miningforgold

Simply amazing, thanks.

GLA

Cant wait. Good top up time

GLA

@spantrout

Thanks. Am I correct they still retain large no of shares?

@Nopulus

This looks a similar prior transfer:

Based on the Investegate announcement from June 11, 2020, Dr. Robert Zimmer did not dispose of his shares in ImmuPharma PLC to an outside party, but rather transferred 20,000,000 shares to Luca & Associates AG, an entity that he is connected with, and of which he is President and a shareholder.

Key details regarding this transaction include:

Internal Transfer: The move was a transfer of shares rather than a market sale, meaning Dr. Zimmer retained a beneficial interest in the shares through Luca & Associates AG.

Purpose: As a substantial shareholder at the time, this transaction was structured to maintain his connection to the company while consolidating holdings.

Continued Support: Around the same time, Dr. Zimmer was identified as a significant shareholder demonstrating support for the company, and in early 2020, he participated in a subscription for new shares.

Context: Following this transfer and his later retirement from the board in 2021, Dr. Zimmer entered into a lock-in agreement to not dispose of shares in which he has an interest for a specified period, further indicating that the transfer was not a "cashing out" move.

@Nopulus

My mistake I read 26 as 24. However, does he not still retain a big chunk?

"ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and developm8ent company, announces that Dr Robert Zimmer, President & Chief Science Officer has confirmed to the Company that he will not be seeking re-election at the forthcoming Annual General Meeting scheduled for 28 June 2021 and will be retiring from ImmuPharma PLC and leaving the Board with effect from then.

The Board would like to express its gratitude to Dr Zimmer for his 16 years of service and wishes him well for the future.

As a substantial shareholder in ImmuPharma and to demonstrate his continued support of the Company, Dr Zimmer has entered into a lock-in agreement, to not dispose of shares in which he has an interest, for a period of three years or, if earlier than three years, the date of the reporting by the Company of the preliminary results of the next Phase 3 clinical trial of Lupuzor™."

@Nolupus

Most importantly, what you are talking about is history, pre P140 New Patent filing.

What you or us do not know is how many shares he has now bought back post the P140 new patent filing.

GLA

@Arthur

Absolutely.

@Nolupus

Why did that ex-director, who I believe was the co- founder of IMM suddenly decide to leave? Tell us the full story please.

GLA

@Crazy

"Stumble across"????

GLA holders

Watch Willem Middlekoop video on 'why gold falls in a crises'.

Topped up here.

GLA

Based on March 2026 data, Chime Financial, Inc. is a prominent American fintech company that fits this description. As of March 2026, Chime has a reported market cap of approximately $8 billion on an estimated $2 billion in revenue.

Here are the key details:

Profitability: After years of expansion, Chime is described as having narrowing losses and being very close to breaking even, with moments of profitability in early 2024 and 2025, although not yet consistently profitable on an annual basis.

Market Cap/Revenue Ratio: With a $8 billion valuation and $2 billion revenue, it holds a revenue valuation multiple of roughly 3.2x.

Focus: Chime operates as a consumer-facing fintech, offering digital banking services through its app.

Other Notables Mentioned (Q1 2026):

Plaid Inc.: Had an estimated valuation of roughly 1.1x revenue as of March 2026, with a market cap of ~$134M on ~$100M revenue (private valuation data) and was paring losses

GLA

Indeed Hamila

I understand fintech cos are valued on the basis of multiples of Revenue. Considering it is breaking even, net debt near zero after taking into account the one off cash receipt of some £10 m it is going to receive and Revenues of over 100m, even if the co was valued at a multiple of 1 x Revenue , I am guessing it should be valued at over £ 100m bearing in mind its future growth prospects? It is currently valued at a 1/10 of this. Am I missing something?